Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine plus Oxybutynin in Obstructive Sleep Apnea
NCT05550246Phase 2Unknown
- Sponsor
- Brigham and Women's Hospital
- Start
- May 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of atomoxetine, oxybutynin in obstructive sleep apnea (OSA), sponsored by Brigham and Women's Hospital. Status: unknown.
02
Drugs
atomoxetineoxybutynin
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT05550246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05550246.